These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15313894)

  • 1. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis.
    van Doorn R; Dijkman R; Vermeer MH; Out-Luiting JJ; van der Raaij-Helmer EM; Willemze R; Tensen CP
    Cancer Res; 2004 Aug; 64(16):5578-86. PubMed ID: 15313894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
    Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
    Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers.
    van Doorn R; Slieker RC; Boonk SE; Zoutman WH; Goeman JJ; Bagot M; Michel L; Tensen CP; Willemze R; Heijmans BT; Vermeer MH
    J Invest Dermatol; 2016 Sep; 136(9):1876-1884. PubMed ID: 27113428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
    Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
    Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.
    Braun FC; Grabarczyk P; Möbs M; Braun FK; Eberle J; Beyer M; Sterry W; Busse F; Schröder J; Delin M; Przybylski GK; Schmidt CA
    Leukemia; 2011 Sep; 25(9):1494-501. PubMed ID: 21625233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD164 identifies CD4
    Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
    Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome.
    Goswami M; Duvic M; Dougherty A; Ni X
    J Cutan Pathol; 2012 May; 39(5):500-7. PubMed ID: 22515221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA.
    Ni X; Richmond HM; Liao XM; Decker WK; Shiue LH; Shpall EJ; Duvic M
    J Invest Dermatol; 2008 Nov; 128(11):2631-2639. PubMed ID: 18480841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a multiprobe RNase protection assay and junctional sequences to define V beta gene diversity in Sezary syndrome.
    Kono DH; Baccala R; Balderas RS; Kovac SJ; Heald PW; Edelson RL; Theofilopoulos AN
    Am J Pathol; 1992 Apr; 140(4):823-30. PubMed ID: 1562047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
    Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
    Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome.
    van Doorn R; van Kester MS; Dijkman R; Vermeer MH; Mulder AA; Szuhai K; Knijnenburg J; Boer JM; Willemze R; Tensen CP
    Blood; 2009 Jan; 113(1):127-36. PubMed ID: 18832135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular pathogenesis of mycosis fungoides and Sézary syndrome.
    Döbbeling U
    G Ital Dermatol Venereol; 2008 Dec; 143(6):385-94. PubMed ID: 19169211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling.
    León F; Cespón C; Franco A; Lombardía M; Roldán E; Escribano L; Harto A; González-Porqué P; Roy G
    Leukemia; 2002 Aug; 16(8):1470-7. PubMed ID: 12145687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOX expression in different subtypes of cutaneous lymphoma.
    Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
    Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
    Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
    Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
    Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.